This protocol applies to patients with active giant cell arteritis who do not have acute visual loss or amaurosis fugax, and whose disease has relapsed or failed to maintain sustained remission on the standard second-line regimen of tocilizumab or methotrexate combined with glucocorticoid tapering.
The patient received tocilizumab or methotrexate in combination with glucocorticoid tapering — the established approach for GCA without acute visual symptoms.
That line targets sustained remission: absence of clinical signs and symptoms of active giant cell arteritis with normal acute phase reactants for at least 6 months, and the ability to taper glucocorticoids to the target dose without relapse. Failure to achieve or maintain this endpoint triggers escalation to the current protocol.
Active giant cell arteritis is confirmed, with no acute visual loss and no amaurosis fugax. This distinction matters: guidance specifically reserves more intensive glucocorticoid approaches for patients with GCA-related visual symptoms, while this population follows a separate escalation path.
The protocol differentiates between major and minor disease relapse. In both cases, adjustment of glucocorticoid therapy is central to the response, with consideration of whether to initiate or modify adjunctive therapy — a step that becomes particularly relevant after recurrent relapses.
Full sequencing, thresholds for defining relapse severity, and the complete adjunctive therapy strategy are set out in the structured protocol…
Treatment goal: Remission — absence of all clinical signs and symptoms attributable to active giant cell arteritis, and normalisation of ESR and CRP.
the task force recommends limiting the use of intravenous pulse GC therapy to patients with complicated GCA such as those with GCA-related visual symptoms.
In case of major relapse (either with signs or symptoms of ischaemia or progressive vascular inflammation) we recommend reinstitution or dose escalation of GC therapy as recommended for new onset disease.
For minor relapses we recommend an increase in GC dose at least to the last effective dose.
we recommend an increase of the daily GCs dose either to the last effective dose or to 5–15 mg above this dose, the latter being common practice in many centres.
Initiation or modification of adjunctive therapy should be considered particularly after recurrent disease relapses.
Absence of all clinical signs and symptoms attributable to active LVV and normalisation of ESR and CRP
View source ↗